Animal experiments have confirmed that blocking the CXCL12-CXCR4 and CCL3-CCR1/CCR5 axes can inhibit the recruitment of Tregs in the bone marrow microenvironment and delay the progression of leukemia [73] (Figure 2), therefore, targeting the CXCL12-CXCR4 and CCL3-CCR1/CCR5 signaling pathways may become targets of leukemia immunotherapy. Here, CCR5 is linked to leukemia.